New translational perspectives for blood-based biomarkers of PTSD: From glucocorticoid to immune mediators of stress susceptibility

Although biological systems have evolved to promote stress-resilience, there is variation in stress-responses. Understanding the biological basis of such individual differences has implications for understanding Posttraumatic Stress Disorder (PTSD) etiology, which is a maladaptive response to trauma...

Full description

Saved in:
Bibliographic Details
Published in:Experimental neurology 2016-10, Vol.284 (Pt B), p.133-140
Main Authors: Daskalakis, Nikolaos P., Cohen, Hagit, Nievergelt, Caroline M., Baker, Dewleen G., Buxbaum, Joseph D., Russo, Scott J., Yehuda, Rachel
Format: Article
Language:English
Subjects:
Biomarkers
Biomarkers - blood
Cytokines - blood
Disease Susceptibility
Glucocorticoids
Glucocorticoids - blood
Humans
Immune system
Individual differences
Novel treatments
PTSD
Stress
Stress Disorders, Post-Traumatic - blood
Stress Disorders, Post-Traumatic - diagnosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although biological systems have evolved to promote stress-resilience, there is variation in stress-responses. Understanding the biological basis of such individual differences has implications for understanding Posttraumatic Stress Disorder (PTSD) etiology, which is a maladaptive response to trauma occurring only in a subset of vulnerable individuals. PTSD involves failure to reinstate physiological homeostasis after traumatic events and is due to either intrinsic or trauma-related alterations in physiological systems across the body. Master homeostatic regulators that circulate and operate throughout the organism, such as stress hormones (e.g., glucocorticoids) and immune mediators (e.g., cytokines), are at the crossroads of peripheral and central susceptibility pathways and represent promising functional biomarkers of stress-response and target for novel therapeutics.
ISSN:0014-4886
1090-2430
DOI:10.1016/j.expneurol.2016.07.024